FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pulmonology, and concerns treating a condition which is amenable by inhibiting leukotriene-A4-hydrolase activity in a human patient. For this purpose, the above human patient is administered a compound which is 4-{[(1S,4S)-5-({4-[4-oxazol-2-ylphenoxy]phenyl}methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl} benzoic acid, in dose of 5 to 50 mg, wherein said compound is administered orally, and wherein said condition is an inflammation of the lungs or an inflammation of the airways, selected from a group consisting of cystic fibrosis, pulmonary fibrosis, chronic obstructive pulmonary disease and interstitial lung disease associated with systemic sclerosis. Said dose provides blood plasma content exceeding IC50 for at least 12 hours.
EFFECT: invention provides effective treatment of the above conditions in the patient.
14 cl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2-PHENYLAMINO-3-CYANOPYRAZOLO[1,5-A]PYRIMIDINE, USEFUL AS INHIBITOR OF LEUKOTRIENE A HYDROLASE | 2014 |
|
RU2678196C2 |
| 1H-INDAZOLES, 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES, SYNTHESIS THEREOF AND USE | 2004 |
|
RU2389729C2 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
| LEUKOTRIENE A4-HYDROLASE INHIBITORS | 2014 |
|
RU2690489C2 |
| LEUKOTRIENE A4-HYDROLASE INHIBITORS | 2014 |
|
RU2696559C2 |
| BICYCLIC OXAZINE- OR THIAZINE-OXAZOLIDINONES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND METHODS OF TREATMENT OF PATIENTS WITH MICROBIAL INFECTIONS | 1995 |
|
RU2128660C1 |
| NEW COMPOUNDS USED AS POTASSIUM CHANNEL OPENERS | 2018 |
|
RU2779131C2 |
| TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND | 2016 |
|
RU2715413C2 |
| DERIVANTS OF BICYCLO[2, 2, 1] HEPT-7-YLAMINE AND THEIR APPLICATIONS | 2006 |
|
RU2442771C2 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
